Cited by 235Mesenchymal stem cell researchAnalytical Methods in PharmaceuticalsAcute Ischemic Stroke Management

Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke

Open access
Vu, Quynh, Xie, Kate, Eckert, Mark, Zhao, Weian, Cramer, Steven C.·2014·Neurology

Abstract

To address patient safety, a drug product is chromatographically screened for organic leachables. Similarly, medical device and packaging system extracts are chromatographically screened for organic extractables as probable leachables. To protect patient health, the screening methods must respond to all potentially unsafe substances. To be efficient, analytes determined to be below the toxicologically relevant threshold are removed from consideration, before the subsequent analytical tasks of identification and quantitation are performed. The analytical evaluation threshold (AET) was established for use as a toxicologically relevant threshold to differentiate between chromatographic peaks that are unlikely to be unsafe (and thus do not need safety assessment) and those that are possibly unsafe (and thus require safety assessment). In practice, the instrumental response associated with the AET is determined using surrogate standards. It is then assumed that the response strength for an unknown extractable is equivalent to that for the surrogate standard at the AET concentration (i.e., relative response factor = 1). It is an unfortunate reality that response factors vary for different compounds on nearly all detector systems. This complicates the application of the AET and can result in a failure to include potentially toxicologically relevant compounds in the identification phase of the analysis. To ensure protection, an uncertainty factor was built into the AET equation which adjusts downward the AET to address response variation. While this mechanism does increase the protectiveness of the AET, it assumes that the available methodology and instrumentation is sufficiently sensitive to reach the new lowered AET value. However, in some cases the response variation is so great and the resulting uncertainty factor so large that the revised AET is below the achievable sensitivity specifications of even state-of-the art, expertly operated instrumental technologies. The only option then remaining is to concentrate the samples which can result in adverse effects on analysis quality − counteracting the perceived benefit of lowering the AET. This manuscript demonstrates how an analytical strategy based on methods with multiple complementary and orthogonal detection techniques (a multidetector approach) mitigates the problem of response factor variation and thus eliminates the need for large uncertainty factors and the resulting lower AET values. The primary concept is that all analytes only need to be effectively detected by at least one of the combination of detectors applied and it is this effective technique (combination of all detectors and chromatographic methods utilized) that is used to perform the AET assessment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000000278

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MSC transplantation for acute stroke improves patient symptoms and promotes neurological recovery in ischemic stroke patients without adverse effects.

    “MSC transplantation for acute stroke improves patient symptoms and promotes neurological recovery in ischemic stroke patients without adverse effects.360–362”

    From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [362]

    The Abstract reports improved outcomes in animal models of ischemic stroke, and the Discussion describes favorable behavioral outcomes after MSC treatment. It does not establish symptom improvement or neurological recovery in stroke patients; the Discussion says MSCs have yet to prove effective in humans. The paper mentions an excellent safety record in human trials for other diseases, not an absence of adverse effects in ischemic stroke patients (page numbers unavailable in our copy). (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 58 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Cramer SC. Issues in clinical trial methodology for brain repair after stroke. In: Cramer SC, Nudo RJ, editors. Brain Repair After Stroke. Cambridge, UK: Cambridge Univer- sity Press; 2010:173-182.
  2. Institute of Medicine. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. Washington, DC: National Academies Press; 2013.

Cited by

Sorted by citations

Authors
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C.
Affiliations
University of California, Irvine (US)
Venue
Neurology
Published
2014-04-08
Volume
82
Issue
14
Pages
1277-1286
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2169093550
Cited by
235
References
58
Citations by year
2026: 8 · 2025: 7 · 2024: 11 · 2023: 22 · 2022: 29 · 2021: 31 · 2020: 20 · 2019: 18 · 2018: 22 · 2017: 22 · 2016: 20 · 2015: 23 · 2014: 2
FWCI
3.41
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute of Neurological Disorders and Stroke (R01NS059909)
  • National Center for Research Resources (5M011 RR-00827-29, M01RR000827)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24HD074722)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
Keywords
mesenchymal stem cells, ischemic stroke, preclinical research, patient safety, uncertainty factors
MeSH terms
Animals, Brain Ischemia, Disease Models, Animal, Humans, Outcome Assessment, Health Care, Recovery of Function, Stroke, Mice, Rats, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review